Want to see PALI full AI Analyst Report?
Top Page
Palisade Bio
(NASDAQ:PALI)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.00
▼(-1.48% Downside)
Action:Reiterated
Date:08/11/26
The score is held back primarily by weak financial performance: pre-revenue results, widening losses, and sustained negative free cash flow with rising burn. Technicals are a modest positive as the stock trades above key moving averages with moderately positive momentum. Valuation remains constrained by losses (negative P/E), and the recent increase in authorized shares adds potential dilution risk despite improving financing flexibility.
Positive Factors
Balance-sheet strength
Low leverage and a sizable equity base give Palisade structural financial flexibility uncommon for pre-revenue biotechs. This supports continued R&D spending and reduces near-term refinancing risk, lengthening the runway for clinical programs and strategic optionality over months.
Negative Factors
Pre-revenue with widening losses
The company remains essentially pre-revenue while operating losses roughly doubled year-over-year. Persistent negative profitability and rising spending compress returns and increase reliance on external capital, pressuring the business if clinical progress or funding access slows.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
Low leverage and a sizable equity base give Palisade structural financial flexibility uncommon for pre-revenue biotechs. This supports continued R&D spending and reduces near-term refinancing risk, lengthening the runway for clinical programs and strategic optionality over months.
Read all positive factors
Palisade Bio (PALI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$341.57M
Dividend YieldN/A
Average Volume (3M)4.07M
Price to Earnings (P/E)―
Beta (1Y)-0.03
Revenue GrowthN/A
EPS Growth91.31%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.53
Shares Outstanding174,270,550
10 Day Avg. Volume2,909,743
30 Day Avg. Volume4,071,253
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside244.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.24
Revenue Forecast (FY)N/A
Palisade Bio Business Overview & Revenue Model
Company Description
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The c...
How the Company Makes Money
null...
Palisade Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 500.00K | 0.00 | 0.00 | 250.00K | 0.00 | 0.00 |
| Gross Profit | 500.00K | 0.00 | 0.00 | 250.00K | 0.00 | 0.00 |
| EBITDA | -33.22M | -16.77M | -14.42M | -12.28M | -14.24M | -24.22M |
| Net Income | -31.94M | -16.78M | -14.44M | -12.30M | -14.26M | -26.62M |
Balance Sheet | ||||||
| Total Assets | 127.31M | 134.34M | 10.88M | 14.05M | 15.76M | 12.51M |
| Cash, Cash Equivalents and Short-Term Investments | 125.17M | 133.38M | 9.82M | 12.43M | 12.38M | 10.49M |
| Total Debt | 0.00 | 71.00K | 169.00K | 369.00K | 404.00K | 199.00K |
| Total Liabilities | 5.57M | 4.96M | 3.39M | 2.74M | 3.28M | 5.15M |
| Stockholders Equity | 121.75M | 129.38M | 7.49M | 11.31M | 12.48M | 7.37M |
Cash Flow | ||||||
| Free Cash Flow | -18.19M | -10.85M | -12.19M | -11.14M | -13.37M | -14.77M |
| Operating Cash Flow | -18.19M | -10.85M | -12.19M | -11.13M | -13.36M | -14.77M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -4.00K | -10.00K | -54.00K |
| Financing Cash Flow | 137.97M | 134.44M | 9.58M | 11.19M | 15.26M | 24.61M |
Palisade Bio Technical Analysis
Positive
2.03
Price Trends
1.94
Positive
1.98
Positive
1.93
Positive
Market Momentum
0.04
Negative
57.04
Neutral
72.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PALI, the sentiment is Positive. The current price of 2.03 is above the 20-day moving average (MA) of 2.01, above the 50-day MA of 1.94, and above the 200-day MA of 1.93, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 57.04 is Neutral, neither overbought nor oversold. The STOCH value of 72.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PALI.
Palisade Bio Risk Analysis
Palisade Bio disclosed 52 risk factors in its most recent earnings report. Palisade Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Palisade Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $201.47M | -2.13 | -135.60% | ― | 291.42% | 11.70% | |
53 Neutral | $188.77M | -1.56 | -87.05% | ― | ― | -29.66% | |
52 Neutral | $341.57M | -4.04 | -33.47% | ― | ― | 91.31% | |
52 Neutral | $265.66M | -4.49 | -133.09% | ― | 986.14% | 45.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $291.00M | -0.24 | -96.80% | ― | ― | -1.48% |
* Healthcare Sector Average
PALI
Palisade Bio
2.15
1.33
162.20%
CRBP
Corbus Pharmaceuticals
10.08
0.45
4.67%
ELDN
Eledon Pharmaceuticals
3.70
1.10
42.31%
OBIO
Orchestra BioMed Holdings
4.45
1.79
67.29%
PYXS
Pyxis Oncology
3.01
1.88
166.37%
Palisade Bio Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Palisade Bio Shareholders Approve Charter Amendments, Governance Matters
Positive
Jun 11, 2026
At its annual meeting on June 10, 2026, Palisade Bio stockholders approved all seven proposals on the ballot, including the election of four directors to serve until the 2027 meeting and ratification of Baker Tilly US, LLP as independent auditor f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.